MOVE Medacta Group

Medacta further expands in Rancate, Switzerland, doubling its production capability to support the future growth

Medacta Group SA / Key word(s): Expansion/Expansion
Medacta further expands in Rancate, Switzerland, doubling its production capability to support the future growth

29.11.2023 / 19:00 CET/CEST


Media Release

Medacta further expands in Rancate, Switzerland, doubling its production capability to support the future growth

CASTEL SAN PIETRO, Switzerland, 29 November 2023 – Medacta, a Swiss company featuring innovative, personalized, and sustainable solutions for joint replacement, sports medicine, and spine surgeries, announces the start of the expansion of the new facility construction in Rancate, complementing the one already underway in Castel San Pietro, supporting future growth, and increased in-house production, needed to meet the high demand for Medacta products.

“Today we celebrate another important milestone for Medacta. Built on strong values, our growth confirms our dedication to fostering our international expansion to meet patients, medical professionals, and healthcare systems’ needs and expectations. We are excited to keep making investments in our future here in Switzerland, Ticino, where our company was founded,” says Francesco Siccardi, CEO of Medacta.

Medacta's continuous investment and commitment to the Castel San Pietro and Rancate facilities is fundamental for the Company’s forecasted growth. The Rancate expansion will add approximately 9,500 square meters over the next three years, while the Castel San Pietro growth will extend the production area by about 5,300 square meters and will be operational in the first quarter of 2024, with the creation of numerous new jobs. With this expansion, the two hubs of cutting-edge technology will double Medacta’s production capability, enabling it to continue innovating responsibly for the benefit of patients, medical professionals, healthcare systems, and the local community.

Medacta is also investing in its logistics and distribution infrastructure to ensure efficient delivery of its products to customers worldwide. As part of Medacta’s expansion plan, in 2023, a new Distribution Center in Memphis, Tennessee was opened, Medacta Americas Operations, to serve the US market. Additionally, Medacta has identified a potential location in northern Italy, to establish a second Distribution Center, Medacta Europe Operations, which will serve the European market. The new facility is expected to have up to 10,000 square meters of space and should become operational in mid-2025.

The above plan is a further development of the already announced expansion, when Medacta celebrated the opening of its new offices in Rancate, with an expansion of 2,100 square meters.

In total, Medacta plants in Ticino are foreseen to cover more than 36,800 square meters.

Contact
Medacta International SA
Gianluca Olgiati     
Senior Director Global Marketing  
Phone: 0

 

ABOUT MEDACTA

Medacta is an international company specializing in the design, production, and distribution of innovative orthopaedic products, as well as in the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta is active in joint replacement, spine surgery, and sports medicine. Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Medacta's innovation, forged by close collaboration with surgeon experts globally, began with minimally invasive surgical techniques and has evolved into personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 50 countries. Follow us on , , , and .


Additional features:

File:


End of Media Release


Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone:
E-mail:
Internet:
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 1784799

 
End of News EQS News Service

1784799  29.11.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1784799&application_name=news&site_id=research_pool
EN
29/11/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medacta Group

Maria Vara ... (+3)
  • Maria Vara
  • Oscar Haffen Lamm
  • Valliant Campagne

Suspension of coverage

From 2nd of June we are suspending coverage of companies below due to a reallocation of resources. Our prior estimates should no longer be used as an indicator for the company moving forward.INNATE PHARMAINVENTIVAMEDACTAMEDARTISONWARD MEDICALVALNEVA

Maria Vara
  • Maria Vara

Medacta: model update - Buy rating reiterated, unchanged CHF160 PT

We update our model following the publication of the company's annual report. No changes have been applied to our revenue forecast as FY 2024 results and 2025 guidance are aligned with our estimates. On the P&L, we have softened our S&M expenses expectation as these stood more towards 35.5%

 PRESS RELEASE

Medacta publishes 2025 Annual General Meeting invitation

Medacta Group SA / Key word(s): AGMEGM Medacta publishes 2025 Annual General Meeting invitation 08.04.2025 / 10:00 CET/CEST Press Release                     Medacta publishes 2025 Annual General Meeting invitation  CASTEL SAN PIETRO, 8 April 2025 – Medacta Group SA (“Medacta”, SIX:MOVE) published today the invitation to the Annual General Meeting (“AGM”) which will take place on Wednesday, 7 May 2025 at 11.00 a.m. at the Group premises in Via alla Rossa 6, Rancate, Switzerland. Shareholders can register to attend the Annual General Meeting in person but will also be abl...

Maria Vara
  • Maria Vara

Medacta: Exceptional FY2024 to fuel sustainable growth, adj. EBITDA hi...

Medacta reported preliminary unaudited FY 2024 revenue in early February; hence, the EUR590.6m figure was not a surprise. Nonetheless, we may highlight again that all four business lines delivered above the market growth with double-digit cc gains with a broad base geographical contribution. Gross

Maria Vara
  • Maria Vara

Medacta: expanding SportsMed footprint with Parcus Medical acquisition

Medacta expands its SportMeds footprint by acquiring Parcus Medical, a distinguished player with a diverse product family in sports medicine spanning the shoulder, knee, hip, and foot & ankle, with FY2024 unaudited revenues of USD16m. The acquisition not only expands Medacta's offering but also

ResearchPool Subscriptions

Get the most out of your insights

Get in touch